{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:48:44Z","timestamp":1790419724922,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T00:00:00Z","timestamp":1543449600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00431-018-3299-3","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T07:03:06Z","timestamp":1543474986000},"page":"323-329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Osteoporosis-pseudoglioma syndrome: clinical, genetic, and treatment-response study of 10 new cases in Greece"],"prefix":"10.1007","volume":"178","author":[{"given":"Iordanis","family":"Papadopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Bountouvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8032-9994","authenticated-orcid":false,"given":"Achilleas","family":"Attilakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Gole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argirios","family":"Dinopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melpomeni","family":"Peppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polyxeni","family":"Nikolaidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,29]]},"reference":[{"key":"3299_CR1","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1086\/497706","volume":"77","author":"M Ai","year":"2005","unstructured":"Ai M, Heeger S, Bartels CF, Schelling DK (2005) Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. Am J Hum Genet 77:741\u2013753","journal-title":"Am J Hum Genet"},{"key":"3299_CR2","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1002\/jbmr.530","volume":"26","author":"HP Arantes","year":"2011","unstructured":"Arantes HP, Barros ER, Kunii I, Bilezikian JP, Lazaretti-Castro M (2011) Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma. J Bone Miner Res 26:2823\u20132826","journal-title":"J Bone Miner Res"},{"key":"3299_CR3","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1515\/JPEM.2008.21.8.811","volume":"21","author":"ER Barros","year":"2008","unstructured":"Barros ER, Dias da Silva MR, Kunii IS, Lazaretti-Castro M (2008) Three years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndrome (OPPG) carrying an LRP5 mutation. J Pediatr Endocrinol Metab 21:811\u2013818","journal-title":"J Pediatr Endocrinol Metab"},{"key":"3299_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1515\/JPEM.2006.19.3.275","volume":"19","author":"F Bayram","year":"2006","unstructured":"Bayram F, Tanriverdi F, Kurtoglu S et al (2006) Effects of 3\u00a0years of intravenous pamidronate treatment on bone markers and bone mineral density in a patient with osteoporosis-pseudoglioma syndrome (OPPG). J Pediatr Endocrinol Metab 19:275\u2013279","journal-title":"J Pediatr Endocrinol Metab"},{"key":"3299_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.bone.2006.02.069","volume":"39","author":"WM Cheung","year":"2006","unstructured":"Cheung WM, Jin LY, Smith DK et al (2006) A family with osteoporosis pseudoglioma syndrome due to compound heterozygosity of two novel mutations in the LRP5 gene. Bone 39:470\u2013476","journal-title":"Bone"},{"key":"3299_CR6","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/humu.20916","volume":"30","author":"BD Chung","year":"2009","unstructured":"Chung BD, Kayserili H, Ai M, Freudenberg J, \u00dcz\u00fcmc\u00fc A, Uyguner O, Bartels CF, H\u00f6ning S, Ramirez A, Hanisch FG, N\u00fcrnberg G, N\u00fcrnberg P, Warman ML, Wollnik B, Kubisch C, Netzer C (2009) A mutation in the signal sequence of LRP5 in a family with an osteoporosis-pseudoglioma syndrome (OPPG)-like phenotype indicates a novel disease mechanism for trinucleotide repeats. Hum Mutat 30:641\u2013648","journal-title":"Hum Mutat"},{"key":"3299_CR7","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/nm.2388","volume":"17","author":"Y Cui","year":"2011","unstructured":"Cui Y, Niziolek PJ, MacDonald BT et al (2011) Lrp5 functions in bone to regulate bone mass. Nat Med 17:684\u2013691","journal-title":"Nat Med"},{"key":"3299_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/01.mol.0000162326.62419.e4","volume":"16","author":"SL Ferrari","year":"2005","unstructured":"Ferrari SL, Deutsch S, Antonarakis SE (2005) Pathogenic mutations and polymorphisms in the lipoprotein receptor-related protein 5 reveal a new biological pathway for the control of bone mass. Curr Opin Lipidol 16:207\u2013214","journal-title":"Curr Opin Lipidol"},{"key":"3299_CR9","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jsbmb.2006.11.018","volume":"103","author":"JA Fretz","year":"2007","unstructured":"Fretz JA, Zella LA, Kim S, Shevde NK, Pike JW (2007) 1,25-Dihydroxyvitamin D3 induces expression of the Wnt signaling co-regulator LRP5 via regulatory elements located significantly downstream of the gene's transcriptional start site. J Steroid Biochem Mol Biol 103:440\u2013445","journal-title":"J Steroid Biochem Mol Biol"},{"key":"3299_CR10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","volume":"107","author":"Y Gong","year":"2001","unstructured":"Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GCM, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, de Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, J\u00fcppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513\u2013523","journal-title":"Cell"},{"key":"3299_CR11","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1359\/JBMR.050101","volume":"20","author":"H Hartikka","year":"2005","unstructured":"Hartikka H, Makitie O, Mannikko M et al (2005) Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children. J Bone Miner Res 20:783\u2013789","journal-title":"J Bone Miner Res"},{"key":"3299_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bone.2016.10.018","volume":"96","author":"CM Jacobsen","year":"2017","unstructured":"Jacobsen CM (2017) Application of anti-sclerostin therapy in non-osteoporosis disease models. Bone 96:18\u201323","journal-title":"Bone"},{"key":"3299_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1083\/jcb.200201089","volume":"157","author":"M Kato","year":"2002","unstructured":"Kato M, Patel MS, Levasseur R, Lobov I, Chang BHJ, Glass DA II, Hartmann C, Li L, Hwang TH, Brayton CF, Lang RA, Karsenty G, Chan L (2002) Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157:303\u2013314","journal-title":"J Cell Biol"},{"key":"3299_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.molmed.2005.01.004","volume":"11","author":"MA Koay","year":"2005","unstructured":"Koay MA, Brown MA (2005) Genetic disorders of the LRP5-Wnt signalling pathway affecting the skeleton. Trends Mol Med 11:129\u2013137","journal-title":"Trends Mol Med"},{"key":"3299_CR15","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/ejhg.2011.42","volume":"19","author":"CM Laine","year":"2011","unstructured":"Laine CM, Chung BD, Susic M, Prescott T, Semler O, Fiskerstrand T, D'Eufemia P, Castori M, Pekkinen M, Sochett E, Cole WG, Netzer C, M\u00e4kitie O (2011) Novel mutations affecting LRP5 splicing in patients with osteoporosis-pseudoglioma syndrome (OPPG). Eur J Hum Genet 19:875\u2013881","journal-title":"Eur J Hum Genet"},{"key":"3299_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11154-015-9315-2","volume":"16","author":"N Lara-Castillo","year":"2015","unstructured":"Lara-Castillo N, Johnson ML (2015) LRP receptor family member associated bone disease. Rev Endocr Metab Disord 16:141\u2013148","journal-title":"Rev Endocr Metab Disord"},{"key":"3299_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1586\/17446651.3.3.337","volume":"3","author":"R Levasseur","year":"2008","unstructured":"Levasseur R (2008) Treatment and management of osteoporosis-pseudoglioma syndrome. Expert Rev Endocrinol Metab 3:337\u2013348","journal-title":"Expert Rev Endocrinol Metab"},{"key":"3299_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jbspin.2004.10.008","volume":"72","author":"R Levasseur","year":"2005","unstructured":"Levasseur R, Lacombe D, de Vernejoul MC (2005) LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders. Joint Bone Spine 72:207\u2013214","journal-title":"Joint Bone Spine"},{"issue":"6","key":"3299_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/157488611795684712","volume":"2011","author":"L Mosekilde","year":"2011","unstructured":"Mosekilde L, Torring O, Rejnmark L (2011) Emerging anabolic treatments in osteoporosis. Curr Drug Saf 2011(6):62\u201374","journal-title":"Curr Drug Saf"},{"key":"3299_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.2174\/1871530313666131224114530","volume":"13","author":"A Papadopoulou","year":"2013","unstructured":"Papadopoulou A, Gole E, Nicolaidou P (2013) Hereditary rickets. How genetic alterations explain the biochemical and clinical phenotypes. Endocr Metab Immune Disord Drug Targets 13:324\u2013334","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"3299_CR21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/humu.20191","volume":"26","author":"M Qin","year":"2005","unstructured":"Qin M, Hayashi H, Oshima K, Tahira T, Hayashi K, Kondo H (2005) Complexity of the genotype-phenotype correlation in familial exudative vitreoretinopathy with mutations in the LRP5 and\/or FZD4 genes. Hum Mutat 26:104\u2013112","journal-title":"Hum Mutat"},{"key":"3299_CR22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1365-2265.2009.03680.x","volume":"72","author":"A Saarinen","year":"2010","unstructured":"Saarinen A, Saukkonen T, Kivela T et al (2010) Low density lipoprotein receptor-related protein 5 (LRP5) mutations and osteoporosis, impaired glucose metabolism and hypercholesterolaemia. Clin Endocrinol 72:481\u2013488","journal-title":"Clin Endocrinol"},{"key":"3299_CR23","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1097-2765(00)80327-5","volume":"5","author":"VS Spiegelman","year":"2000","unstructured":"Spiegelman VS, Slaga TJ, Pagano M, Minamoto T, Ronai Z, Fuchs SY (2000) Wnt\/beta-catenin signaling induces the expression and activity of betaTrCP ubiquitin ligase receptor. Mol Cell 5:877\u2013882","journal-title":"Mol Cell"},{"key":"3299_CR24","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.bone.2008.04.020","volume":"43","author":"EA Streeten","year":"2008","unstructured":"Streeten EA, McBride D, Puffenberger E, Hoffman ME, Pollin TI, Donnelly P, Sack P, Morton H (2008) Osteoporosis-pseudoglioma syndrome: description of 9 new cases and beneficial response to bisphosphonates. Bone 43:584\u2013590","journal-title":"Bone"},{"key":"3299_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bone.2015.04.007","volume":"77","author":"EA Streeten","year":"2015","unstructured":"Streeten EA, Ramirez S, Eliades M, Jaimungal S, Chandrasekaran S, Kathleen R, Holmes Morton D, Puffenberger EG, Herskovitz R, Leonard MB (2015) Fractures on bisphosphonates in osteoporosis pseudoglioma syndrome (OPPG): pQCT shows poor bone density and structure. Bone 77:17\u201323","journal-title":"Bone"},{"key":"3299_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000336193","volume":"77","author":"B Tuysuz","year":"2012","unstructured":"Tuysuz B, Bursali A, Alp Z, Suyugul N, Laine CM, Makitie O (2012) Osteoporosis-pseudoglioma syndrome: three novel mutations in the LRP5 gene and response to bisphosphonate treatment. Horm Res Paediatr 77:115\u2013120","journal-title":"Horm Res Paediatr"},{"key":"3299_CR27","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1093\/hmg\/ddn047","volume":"17","author":"CH Xia","year":"2008","unstructured":"Xia CH, Liu H, Cheung D, Wang M, Cheng C, du X, Chang B, Beutler B, Gong X (2008) A model for familial exudative vitreoretinopathy caused by LPR5 mutations. Hum Mol Genet 17:1605\u20131612","journal-title":"Hum Mol Genet"},{"key":"3299_CR28","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1067\/mpd.2000.107838","volume":"137","author":"M Zacharin","year":"2000","unstructured":"Zacharin M, Cundy T (2000) Osteoporosis pseudoglioma syndrome: treatment of spinal osteoporosis with intravenous bisphosphonates. J Pediatr 137:410\u2013415","journal-title":"J Pediatr"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00431-018-3299-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-018-3299-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-018-3299-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T19:12:07Z","timestamp":1574968327000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00431-018-3299-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,29]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["3299"],"URL":"https:\/\/doi.org\/10.1007\/s00431-018-3299-3","relation":{},"ISSN":["0340-6199","1432-1076"],"issn-type":[{"value":"0340-6199","type":"print"},{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,29]]},"assertion":[{"value":"22 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol was approved by the Institutional Review Board of the University Hospital \u201cAttikon.\u201d","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no financial relationships relevant to this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosure"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the participants and the parents of the participating children.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All the authors declare that they have no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}